Business Wire
http://www.alkermes.com
January 02, 2013 04:00 PM Eastern Daylight Time 

Alkermes’ Corporate Presentation to be Webcast at the 31st Annual J.P. Morgan Healthcare Conference

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the 31st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2013, at 8:00 a.m. PST (11:00 a.m. EST/4:00 p.m. GMT) from the Westin St. Francis Hotel in San Francisco. The presentation may be accessed under the Investor tab on www.alkermes.com and will be archived for 14 days.

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Contacts

Alkermes plc
Eva Stroynowski, +1 781 609 6823
Corporate Communications

Recent Stories

  • View Press Release
    Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 38th Annual dbAccess Health Care Conference
    May 23, 2013
    DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Deutsche Bank 38th Annual dbAccess Health Care Conference on Wednesd... more »
  • View Press Release
    Alkermes plc Reports Financial Results for Fiscal Year 2013 and Provides Financial Expectations
    May 23, 2013
    DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today reported financial results for its fourth quarter and fiscal year ended March 31, 2013. The company also announced that it has changed its... more »
  • View Press Release
    Alkermes Announces Data on ALKS 5461 and ALKS 3831 to Be Presented at 53rd Annual NCDEU Meeting
    May 22, 2013
    DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced that clinical data on ALKS 5461, a novel drug candidate for major depressive disorder (MDD) in patients who have an inadequate r... more »
More Stories
RSS feed for Alkermes plc
http://www.alkermes.com

Release Versions

  • EON: Enhanced Online News

Company Information Center

Alkermes plc RSS feed for Alkermes plc

NASDAQ:ALKS

Share

  • Facebook
  • Twitter
  • LinkedIn
  • Delicious
  • Reddit
  • StumbleUpon
  • Digg
  • MySpace
  • Newsvine
  • Google Bookmark
  • Yahoo! Bookmark
  • EmailEmail
Tweet
  • EmailEmail
All News
Business Wire

Site Navigation

  • Home
    • Home
    • Submit a Press Release
  • Services
    • Overview
    • Targeting
    • Distribution
    • Financial Disclosure
    • Measurement & Analytics
    • Event News Services
    • Media & Journalist Tools
  • News
    • All News
    • News with Multimedia
    • News by Industry
    • News by Subject
    • News by Language
    • Tradeshows & Events
    • Earnings & Conference Calls
  • Education
    • Overview
    • Sample Press Release
    • FAQ
    • Find Your News Online
    • How-to
    • Disclosure Resources
    • White Papers
  • About Us
    • Overview
    • Become a Member
    • Contact Us
    • Follow Us
    • Jobs
    • Business Wire Newsroom

Search

Advanced News Search
  • Log In
  • Sign Up

Follow Us

  • Twitter
  • LinkedIn

More from Business Wire

  • Blog
  • Apps
  • Canada
  • UK/Ireland
  • Deutschland
  • France
  • Italy
  • Japan
  • EON: Enhanced Online News
  • Tradeshownews.com
  • PYMNTS.com

Business Wire Information

  • Contact Us
  • Privacy Statement
  • Terms of Use
  • ©2013 Business Wire